[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Reports Positive Migraine Drug Results in Phase 3 Trial",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive. The study evaluated the tolerability, safety, and efficacy of atogepant (marketed as QULIPTA or AQUIPTA) compared to topiramate for the preventive treatment of […]",
    "url": "https://finnhub.io/api/news?id=ab086b87557527a07533e9ae02ca2855154b2b3517a87e5a5f57ba5ae2ea2aef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750800115,
      "headline": "AbbVie (ABBV) Reports Positive Migraine Drug Results in Phase 3 Trial",
      "id": 135520577,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive. The study evaluated the tolerability, safety, and efficacy of atogepant (marketed as QULIPTA or AQUIPTA) compared to topiramate for the preventive treatment of […]",
      "url": "https://finnhub.io/api/news?id=ab086b87557527a07533e9ae02ca2855154b2b3517a87e5a5f57ba5ae2ea2aef"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know",
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=09aafd58ef04bc7b1806ff7377a833cdb14c672d8de840c2ed87c9c944b66f38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750770004,
      "headline": "Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know",
      "id": 135506353,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=09aafd58ef04bc7b1806ff7377a833cdb14c672d8de840c2ed87c9c944b66f38"
    }
  },
  {
    "ts": null,
    "headline": "Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?",
    "summary": "ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.",
    "url": "https://finnhub.io/api/news?id=3ecf1da5251c6d2c303b3c305bef6437947dfff1c6835864825cb9fd2610054a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750767720,
      "headline": "Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?",
      "id": 135498818,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.",
      "url": "https://finnhub.io/api/news?id=3ecf1da5251c6d2c303b3c305bef6437947dfff1c6835864825cb9fd2610054a"
    }
  },
  {
    "ts": null,
    "headline": "Age-Related Vision Dysfunction Market Research 2025-2035 | Kodiak Sciences, Genentech, and AbbVie Drive Innovations Through Advanced, Sustainable Solutions",
    "summary": "The global age-related vision dysfunction (ARVD) market is witnessing robust growth due to the aging population and heightened awareness of eye health. Age-related vision dysfunction encompasses impairments like macular degeneration, cataracts, and glaucoma, affecting quality of life. The market is thriving with innovative solutions, including pharmaceuticals, surgeries, and digital health technologies such as AI diagnostics and telemedicine. Despite economic and regulatory hurdles, advancements",
    "url": "https://finnhub.io/api/news?id=c9eb4c2dcf684a0986168da30767c4112a8f5194c0c30efd7feecad2a10f558c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750758660,
      "headline": "Age-Related Vision Dysfunction Market Research 2025-2035 | Kodiak Sciences, Genentech, and AbbVie Drive Innovations Through Advanced, Sustainable Solutions",
      "id": 135498820,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The global age-related vision dysfunction (ARVD) market is witnessing robust growth due to the aging population and heightened awareness of eye health. Age-related vision dysfunction encompasses impairments like macular degeneration, cataracts, and glaucoma, affecting quality of life. The market is thriving with innovative solutions, including pharmaceuticals, surgeries, and digital health technologies such as AI diagnostics and telemedicine. Despite economic and regulatory hurdles, advancements",
      "url": "https://finnhub.io/api/news?id=c9eb4c2dcf684a0986168da30767c4112a8f5194c0c30efd7feecad2a10f558c"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'",
    "summary": "Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. Read about two such stocks that are undervalued vs. historical norms.",
    "url": "https://finnhub.io/api/news?id=bcae1d83887a65e6c9f9053eb28696afd7ae4c7b3be1ead657c7a557d5bd0369",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750752000,
      "headline": "2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'",
      "id": 135496728,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1652791120/image_1652791120.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. Read about two such stocks that are undervalued vs. historical norms.",
      "url": "https://finnhub.io/api/news?id=bcae1d83887a65e6c9f9053eb28696afd7ae4c7b3be1ead657c7a557d5bd0369"
    }
  }
]